Video

The role of doublet and triplet therapies in prostate cancer

Author(s):

Urology Times staff

“There are many studies now that have shown that these doublets and triplets seem to be better than just ADT alone,” says William K. Oh, MD.

In this video, William K. Oh, MD, discusses the rise of doublet and triplet therapies in the treatment of prostate cancer, and what questions are still being investigated related to these novel treatments.Oh is a clinical professor of medicine at the Icahn School of Medicine, Mount Sinai in New York, New York.

Related Videos
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Related Content
Phase 3 trial launches ArteraAI Prostate Test for treatment selection
March 11th 2025

Phase 3 trial launches ArteraAI Prostate Test for treatment selection

Hannah Clarke
The goal of the trial is to improve quality of life by identifying patients who can safely reduce or avoid treatment with hormone therapy.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Trial of 64Cu/67Cu-SAR-bisPSMA in mCRPC progresses to dose expansion phase
March 5th 2025

Trial of 64Cu/67Cu-SAR-bisPSMA in mCRPC progresses to dose expansion phase

Hannah Clarke
The safety review committee recommended that the phase 2 portion proceed with the 8 GBq dose.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
FDA updates in urology: February 2025
March 3rd 2025

FDA updates in urology: February 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from February 2025.
Enrollment goal met in trial of Vanquish device for localized prostate cancer
February 27th 2025

Enrollment goal met in trial of Vanquish device for localized prostate cancer

Hannah Clarke
Data from the VAPOR 2 trial are intended to support a submission to the FDA for 510(k) clearance of the device.
© 2025 MJH Life Sciences

All rights reserved.